Zoetis Inc. (ZTS) is a renowned global leader in the animal health industry. Incorporated in 1952 and headquartered in Parsippany, New Jersey, United States, the company has a prominent presence around the globe, offering its products and services in approximately 100 countries.
Zoetis is committed to innovating and serving veterinarians, livestock producers, pet owners, and other animal health professionals. The company's comprehensive portfolio comprises over 300 product lines, covering eight core animal species, including dogs, cats, horses, cattle, swine, poultry, sheep, and fish. Zoetis is known for developing, manufacturing, and commercializing an impressive range of veterinary medicines, vaccines, diagnostic products, genetic tests, biodevices, and a variety of services.
The portfolio includes popular products like Apoquel and Cytopoint for treating allergic dermatitis in dogs, and Draxxin, a leading antibiotic for livestock. Additionally, Zoetis has launched innovative diagnostic products like the WITNESS line of rapid diagnostic tests and ClariFly, a feed supplement to prevent flies in livestock environments.
Zoetis is committed to advancing animal health and well-being worldwide. They continually invest in research and development in anticipation of the evolving needs of animal health. This unrelenting focus on innovation and cutting-edge technology has positioned Zoetis as a frontrunner in their field, enabling them to provide valuable solutions to the widest possible community of customers.
In the financial perspective, Zoetis has been consistently delivering strong performance. The company has been listed on the New York Stock Exchange (NYSE) since 2013 under the ticket name "ZTS". It has progressively grown its shareholder returns, thanks to its robust financials and future-oriented strategy.
Moreover, the company's commitment to corporate responsibility is commendable. Zoetis takes a holistic approach in its operations, taking into account environmental preservation, animal well-being, employee safety, product quality, and corporate governance.
Overall, Zoetis has a rich heritage and a bright future in global animal health, standing as a pillar of industry expertise and customer service. With the drive for continuous growth and commitment to breaking new grounds in animal health, Zoetis is set for remarkable innovations and breakthroughs in the field.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Daymon Loeb, CEO of Ravenstone Capital Management, is focusing on "boring, traditional businesses" with strong fundamentals and reasonable valuations, rather than the AI trade. He has recently bought S&P Global (SPGI-N) due to its dominant market position and attractive valuation despite AI disruption fears, and Berkshire Hathaway (BRK-B-N), believing the market undervalues its intrinsic value and new CEO Greg Abel's leadership. Mastercard (MA-N) is another recent purchase, valued for its global duopoly in payment systems and lack of credit risk.
Hahn Capital Management LLC initiated a new $4.49 million investment in Miami International Holdings, Inc. (NYSE:MIAX) during the third quarter, acquiring 134,065 shares. This stake now constitutes 2.6% of Hahn Capital Management's portfolio. Miami International Holdings recently reported strong quarterly earnings, beating analyst estimates with an EPS of $0.45 and a 243.6% year-over-year revenue increase to $376.18 million.
Freshpet, Inc. (NASDAQ:FRPT) filed a Form 8-K with the SEC on November 4, 2026, disclosing its financial results for the quarter ended September 30, 2026. The filing included a press release, an investor presentation, and a transcript from its earnings call, which discussed non-GAAP financial measures reconciled to GAAP. The report was signed by CFO John G. O'Connor.
Shares of Zoetis Inc. (ZTS) advanced 7.48% to $89.20 on Wednesday, outperforming the broader market. The S&P 500 Index (SPX) rose 1.58%, and the Dow Jones Industrial Average (DJIA) gained 3.03% on the same strong trading day. Despite this gain, Zoetis Inc. remains 32.67% below its 52-week high of $132.49, achieved on February 12th.
This report analyzes Zoetis Inc. Class A (NYSE: ZTS), identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights a breakout underway with compelling upside potential due to no remaining resistance levels above the current price. The analysis provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop levels.
Shares of Zoetis Inc. (ZTS) rose 4.34% to $83.18 on Monday, outperforming its competitors. This gain occurred during a mixed trading session where the Dow Jones Industrial Average increased, but the S&P 500 Index declined. This marks the stock's third consecutive day of gains.
IDEXX Laboratories reported strong Q3 2026 results, beating earnings and revenue estimates and raising its full-year growth outlook for the third time, driven by robust diagnostics volumes despite declining U.S. vet visits. While core diagnostics accelerated, the acquisition of CoVet and its associated costs led to a slight trim in the company's operating margin guidance, creating a point of scrutiny for investors heading into 2027. The company's innovation pipeline, particularly inVue Dx placements and new cancer diagnostic panels, continues to fuel its growth story.
Quest Diagnostics (NYSE:DGX) recently reported third-quarter results, exceeding statutory profit expectations with US$2.78 per share, though revenues were in line with forecasts. Analysts have since updated their models, reaffirming a price target of US$255 and projecting reasonable growth for 2027, with no major changes to their overall outlook for the business. The company is expected to grow its revenue at a rate similar to the broader industry.
This article compares Neogen Corporation (NEOG) and Where Food Comes From, Inc. (WFCF), two companies in the food safety industry, to determine which has better investment prospects. It analyzes their business models, financial performance, growth opportunities, and challenges. While NEOG shows stronger growth potential and operational improvement, WFCF offers a more conservative financial profile with less debt.